All In Biotech

Drug Trial Radar · NCT07304154

Study of KITE-363 in Participants With Autoimmune Neurologic Diseases That Did Not Respond to Usual Treatment

A Phase 1, Open-label, Multiregional, Multicenter, Basket Study Evaluating the Safety and Efficacy of KITE-363, an Autologous Anti-CD19/CD20 CAR T-cell Therapy in Participants With Relapsed/Refractory Autoimmune Neurologic Diseases

Last checked: Nov 19, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

57

Planned (sponsor's estimate)

Start

Apr 10, 2026

Primary completion

Dec 2031

Study completion Dec 2031

Sponsor

Lead sponsor
Kite, A Gilead CompanyGilead Sciences (GILD)
Sponsor type
Industry
First posted
Dec 26, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will have two Phases: Phase 1a and Phase 1b. The goals of this clinical study are to learn more about the study drug KITE-363, by evaluating its safety, tolerability and efficacy in participants with relapsed/refractory autoimmune neurologic diseases. The primary objectives of this study are: * To evaluate the safety and tolerability of KITE-363 in participants with autoimmune neurologic diseases * To determine the recommended dose for Phase 1b * To evaluate the safety and preliminary efficacy of KITE-363 in participants with autoimmune neurologic diseases

Conditions

  • Chronic Inflammatory Demyelinating Polyneuropathy
  • Myasthenia Gravis
  • Multiple Sclerosis

Interventions

  • KITE-363Biological

    A single infusion of CAR-transduced autologous T cells administered as intravenous infusion.

  • FludarabineDrug

    Administered intravenously

  • CyclophosphamideDrug

    Administered intravenously

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase 1a: Percentage of Participants Experiencing Treatment-emergent Adverse Event (TEAEs)Time frame: Up to 3 years
  2. Phase 1a: Percentage of Participants Experiencing Dose-limiting Toxicities (DLTs) After the Infusion of KITE-363Time frame: Up to 28 days
  3. Phase 1b: (All Cohorts) Percentage of Participants Experiencing TEAEsTime frame: Up to 3 years
  4. Phase 1b: Relapsing Forms of MS (RRMS) and Active Secondary-progressive Multiple Sclerosis (aSPMS): Number of New T1 Gadolinium Enhancing (GadE+) Lesions on Magnetic Resonance Imaging (MRI) at Week 12Time frame: Week 12
  5. Phase 1b: Relapsing Forms of MS (RRMS and aSPMS): Number of New and/or Enlarging T2 Lesions on MRI at Week 12Time frame: Week 12
  6. Phase 1b: Progressive Forms of MS (PPMS) and Non-active Secondary-progressive Multiple Sclerosis (naSPMS): Time to Onset of Confirmed Disability Progression Over 12 Weeks (CDP-12)Time frame: Up to 3 years
  7. Phase 1b: Myasthenia Gravis (MG): Proportion of Participants of MG Activities of Daily Living (MG-ADL) RespondersTime frame: Up to 3 years
  8. Phase 1b: CIDP: Proportion of Participants with a ≥ 2 Points Improvement from Baseline in aINCAT Score at Week 24, in the Absence of CIDP Rescue Therapy or Initiation of New Maintenance Immunomodulatory TherapyTime frame: Up to 3 years

Locations

10 sites in 3 countries. Site status is shown where the registry gives one.

  • Hoag Memorial Hospital Presbyterian

    Newport Beach, California · Recruiting

  • Stanford Neuroscience Health Center

    Palo Alto, California · Recruiting

  • Columbia University Irving Medical Center

    New York, New York · Recruiting

  • LDS Hospital - Intermountain Health

    Salt Lake City, Utah · Recruiting

  • Fred Hutchinson Cancer Center

    Seattle, Washington · Recruiting

  • Concord Repatriation General Hospital

    Sydney, New South Wales, Australia · Recruiting

  • Corner Hawkesbury Road and Darcy Road

    Westmead, New South Wales, Australia · Recruiting

  • Centre Intégré Universitaire de Sante et Services Sociaux de L'Est de I'lle de Montreal / installation Hopital Maisonneuve-Rosemont

    Montreal, Canada · Recruiting

  • Jewish General Hospital

    Montreal, Canada · Recruiting

  • The Ottawa Hospital - General Campus

    Ottawa, Canada · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.